Rybelsus
Payments companies reported to CMS as associated with Rybelsus. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Rybelsus, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Rybelsus
These are the largest totals companies reported as associated with Rybelsus. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Vinay Kapoor | Manhasset, NY | Endocrinology, Diabetes & Metabolism | $38,897.60 |
| Amir Harari | Scottsdale, AZ | Endocrinology, Diabetes & Metabolism | $35,593.48 |
| Arelis Madera | Port Charlotte, FL | Endocrinology, Diabetes & Metabolism | $33,676.32 |
| Steve Vacalis | Gastonia, NC | Family Medicine | $33,370.66 |
| Eden Miller | Bend, OR | Family Medicine | $32,698.02 |
| Bernie Ranchero | Altamont, IL | Family Medicine | $30,730.04 |
| Cheng Yang Tuan | San Francisco, CA | Endocrinology, Diabetes & Metabolism | $30,150.28 |
| Jeffrey Unger | Chino, CA | Family Medicine | $29,912.25 |
| Gaston Ponte | Melbourne, FL | Endocrinology, Diabetes & Metabolism | $29,512.08 |
| Mark Corriere | Columbia, MD | Internal Medicine | $29,500.51 |
Prescribed Rybelsus?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.